

GLP-1 Agonists Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology

<https://marketpublishers.com/r/GC9588919AAEEN.html>

Date: March 2025

Pages: 83

Price: US\$ 3,200.00 (Single User License)

ID: GC9588919AAEEN

Abstracts

GLP-1 Agonists Market Summary

Introduction

GLP-1 Agonists are a class of medications that mimic the action of glucagon-like peptide-1, a hormone that regulates blood glucose levels and appetite, making them vital for managing Type 2 Diabetes Mellitus (T2DM) and obesity. Available in parenteral (injectable) and oral forms, they enhance insulin secretion, suppress glucagon release, and slow gastric emptying, offering superior glycemic control and weight loss benefits compared to traditional diabetes treatments. The market operates within the pharmaceutical sector, driven by rising global diabetes and obesity prevalence, increasing demand for effective chronic disease management, and advancements in drug delivery. Innovations in long-acting formulations, oral bioavailability, and combination therapies are shaping the industry, aligning with trends toward personalized medicine, patient convenience, and holistic metabolic health solutions. Novo Nordisk and Eli Lilly dominate as global giants, leveraging extensive portfolios and market reach.

Market Size and Growth Forecast

The global GLP-1 Agonists market is estimated to be valued between USD 38 billion and USD 40 billion in 2025. It is projected to grow at a compound annual growth rate (CAGR) of 10% to 12% from 2025 to 2030, reaching an approximate range of USD 62 billion to USD 70 billion by 2030. This robust growth is driven by escalating chronic disease burdens, expanding therapeutic applications, and strong market leadership by key players.

Regional Analysis

North America holds the largest share of the GLP-1 Agonists market, estimated at 40-45%, with a growth rate of 9-11%. The United States dominates, driven by high T2DM prevalence—over 34 million cases—and obesity rates exceeding 40%, alongside robust healthcare spending and adoption of advanced therapies. Canada contributes with similar trends. Market dynamics include widespread use for obesity management, strong reimbursement frameworks, and innovation leadership by Eli Lilly and Novo Nordisk, reflecting a mature, high-demand market.

Europe accounts for 25-30% of the market, growing at 8-10%. The United Kingdom, Germany, and France lead, supported by universal healthcare systems and rising chronic disease rates. Germany's focus on diabetes care and the UK's obesity initiatives drive demand. Trends emphasize cost-effective parenteral formulations, growing oral GLP-1 adoption, and regulatory support for chronic disease management, balancing innovation with accessibility.

Asia Pacific represents 20-25%, with the highest growth rate of 12-14%. China and India are key drivers, with China's T2DM cases exceeding 140 million and India's obesity rates rising rapidly. Japan focuses on aging populations. Trends include increasing penetration of generics, local production by firms like Huadong Medicine, and government healthcare investments, reflecting rapid market expansion.

The Rest of the World, including Latin America, the Middle East, and Africa, holds 5-10%, growing at 10-12%. Brazil and South Africa lead with growing diabetes prevalence. Trends prioritize affordable therapies, partnerships with global leaders, and uptake in urban centers, supporting regional healthcare development.

Application Analysis

The market is segmented by application into Type 2 Diabetes Mellitus and Obesity.

Type 2 Diabetes Mellitus applications dominate, accounting for 65-70%, with a growth rate of 9-11%. GLP-1 Agonists manage blood glucose effectively, reducing complications. Trends focus on long-acting injectables, combination therapies, and widespread use in North America and Europe, driven by diabetes prevalence.

Obesity applications hold 30-35%, growing at 11-13%. GLP-1 Agonists promote significant weight loss, expanding their use beyond diabetes. Trends include high demand in the U.S., oral formulations for patient convenience, and growing acceptance in Asia Pacific, reflecting obesity's rising global burden.

Product Types Analysis

The market is segmented by product types into Parenteral and Oral.

Parenteral GLP-1 Agonists hold 80-85%, growing at 9-11%. Injectables offer proven efficacy and long-acting options like semaglutide. Trends focus on patient-friendly delivery devices and sustained dominance by Novo Nordisk and Eli Lilly.

Oral GLP-1 Agonists account for 15-20%, growing at 12-14%. Oral forms like Rybelsus improve accessibility. Trends include rapid adoption in Europe and Asia Pacific, driven by patient preference and market expansion efforts.

Key Market Players

Key companies include:

Novo Nordisk: A global leader with blockbuster drugs like Ozempic.

Eli Lilly: Dominates with Trulicity and emerging obesity therapies.

GSK: Focuses on innovative formulations.

AstraZeneca: Offers GLP-1 solutions for diabetes.

Sanofi: Targets chronic disease management.

Huadong Medicine: Leads in China's market.

These firms drive competition through innovation and market reach.

Porter's Five Forces Analysis

Threat of New Entrants: Low to medium. High R&D costs and regulatory hurdles limit entry, though generics pose a future threat.

Threat of Substitutes: Medium. Insulin and other diabetes drugs compete, but GLP-1's dual benefits sustain demand.

Bargaining Power of Buyers: Medium. Patients and insurers demand efficacy, with giants like Novo Nordisk holding leverage.

Bargaining Power of Suppliers: Low. Raw material suppliers have minimal influence due to diversified sourcing.

Competitive Rivalry: High. Novo Nordisk and Eli Lilly dominate, driving innovation and pricing competition.

Market Opportunities and Challenges

Opportunities

Diabetes Epidemic: Rising T2DM cases globally drive demand.

Obesity Management: Expanding use boosts growth, especially in North America.

Oral Adoption: Patient-friendly options increase accessibility.

Challenges

High Costs: Expensive therapies limit access in emerging markets.

Regulatory Hurdles: Stringent approvals slow market entry.

Competition: Generics and biosimilars challenge market share.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 ABBREVIATION AND ACRONYMS

CHAPTER 3 PREFACE

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter Four Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End Users

CHAPTER 5 MARKET TREND ANALYSIS

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

CHAPTER 6 INDUSTRY CHAIN ANALYSIS

6.1 Upstream/Suppliers Analysis

6.2 Glp-1 Agonists Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End Users

CHAPTER 7 LATEST MARKET DYNAMICS

7.1 Latest News

7.2 Merger and Acquisition

7.3 Planned/Future Project

7.4 Policy Dynamics

CHAPTER 8 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN NORTH AMERICA (2020-2030)

8.1 Glp-1 Agonists Market Size

8.2 Glp-1 Agonists Market by End Use

8.3 Competition by Players/Suppliers

8.4 Glp-1 Agonists Market Size by Type

8.5 Key Countries Analysis

8.5.1 United States

8.5.2 Canada

8.5.3 Mexico

CHAPTER 9 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN SOUTH AMERICA (2020-2030)

9.1 Glp-1 Agonists Market Size

9.2 Glp-1 Agonists Market by End Use

9.3 Competition by Players/Suppliers

9.4 Glp-1 Agonists Market Size by Type

9.5 Key Countries Analysis

9.5.1 Brazil

9.5.2 Argentina

9.5.3 Chile

9.5.4 Peru

CHAPTER 10 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN ASIA & PACIFIC (2020-2030)

10.1 Glp-1 Agonists Market Size

10.2 Glp-1 Agonists Market by End Use

10.3 Competition by Players/Suppliers

10.4 Glp-1 Agonists Market Size by Type

10.5 Key Countries Analysis

10.5.1 China

10.5.2 India

10.5.3 Japan

- 10.5.4 South Korea
- 10.5.5 Southeast Asia
- 10.5.6 Australia

CHAPTER 11 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN EUROPE (2020-2030)

- 11.1 Glp-1 Agonists Market Size
- 11.2 Glp-1 Agonists Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Glp-1 Agonists Market Size by Type
- 11.5 Key Countries Analysis
 - 11.5.1 Germany
 - 11.5.2 France
 - 11.5.3 United Kingdom
 - 11.5.4 Italy
 - 11.5.5 Spain
 - 11.5.6 Belgium
 - 11.5.7 Netherlands
 - 11.5.8 Austria
 - 11.5.9 Poland
 - 11.5.10 Russia

CHAPTER 12 HISTORICAL AND FORECAST GLP-1 AGONISTS MARKET IN MEA (2020-2030)

- 12.1 Glp-1 Agonists Market Size
- 12.2 Glp-1 Agonists Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Glp-1 Agonists Market Size by Type
- 12.5 Key Countries Analysis
 - 12.5.1 Egypt
 - 12.5.2 Israel
 - 12.5.3 South Africa
 - 12.5.4 Gulf Cooperation Council Countries
 - 12.5.5 Turkey

CHAPTER 13 SUMMARY FOR GLOBAL GLP-1 AGONISTS MARKET (2020-2025)

- 13.1 Glp-1 Agonists Market Size
- 13.2 Glp-1 Agonists Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Glp-1 Agonists Market Size by Type

CHAPTER 14 GLOBAL GLP-1 AGONISTS MARKET FORECAST (2025-2030)

- 14.1 Glp-1 Agonists Market Size Forecast
- 14.2 Glp-1 Agonists Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Glp-1 Agonists Type Forecast

CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS

- 15.1 Novo Nordisk
 - 15.1.1 Company Profile
 - 15.1.2 Main Business and GLP-1 Agonists Information
 - 15.1.3 SWOT Analysis of Novo Nordisk
 - 15.1.4 Novo Nordisk GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
- 15.2 Eli Lilly
 - 15.2.1 Company Profile
 - 15.2.2 Main Business and GLP-1 Agonists Information
 - 15.2.3 SWOT Analysis of Eli Lilly
 - 15.2.4 Eli Lilly GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
- 15.3 GSK
 - 15.3.1 Company Profile
 - 15.3.2 Main Business and GLP-1 Agonists Information
 - 15.3.3 SWOT Analysis of GSK
 - 15.3.4 GSK GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
- 15.4 AstraZeneca
 - 15.4.1 Company Profile
 - 15.4.2 Main Business and GLP-1 Agonists Information
 - 15.4.3 SWOT Analysis of AstraZeneca
 - 15.4.4 AstraZeneca GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)
- 15.5 Sanofi
 - 15.5.1 Company Profile
 - 15.5.2 Main Business and GLP-1 Agonists Information

15.5.3 SWOT Analysis of Sanofi

15.5.4 Sanofi GLP-1 Agonists Revenue, Gross Margin and Market Share (2020-2025)

Please ask for sample pages for full companies list

Tables and Figures

Table Abbreviation and Acronyms

Table Research Scope of Glp-1 Agonists Report

Table Data Sources of Glp-1 Agonists Report

Table Major Assumptions of Glp-1 Agonists Report

Figure Market Size Estimated Method

Figure Major Forecasting Factors

Figure Glp-1 Agonists Picture

Table Glp-1 Agonists Classification

Table Glp-1 Agonists Applications

Table Drivers of Glp-1 Agonists Market

Table Restraints of Glp-1 Agonists Market

Table Opportunities of Glp-1 Agonists Market

Table Threats of Glp-1 Agonists Market

Table Covid-19 Impact For Glp-1 Agonists Market

Table Raw Materials Suppliers

Table Different Production Methods of Glp-1 Agonists

Table Cost Structure Analysis of Glp-1 Agonists

Table Key End Users

Table Latest News of Glp-1 Agonists Market

Table Merger and Acquisition

Table Planned/Future Project of Glp-1 Agonists Market

Table Policy of Glp-1 Agonists Market

Table 2020-2030 North America Glp-1 Agonists Market Size

Figure 2020-2030 North America Glp-1 Agonists Market Size and CAGR

Table 2020-2030 North America Glp-1 Agonists Market Size by Application

Table 2020-2025 North America Glp-1 Agonists Key Players Revenue

Table 2020-2025 North America Glp-1 Agonists Key Players Market Share

Table 2020-2030 North America Glp-1 Agonists Market Size by Type

Table 2020-2030 United States Glp-1 Agonists Market Size

Table 2020-2030 Canada Glp-1 Agonists Market Size

Table 2020-2030 Mexico Glp-1 Agonists Market Size

Table 2020-2030 South America Glp-1 Agonists Market Size

Figure 2020-2030 South America Glp-1 Agonists Market Size and CAGR

Table 2020-2030 South America Glp-1 Agonists Market Size by Application

Table 2020-2025 South America Glp-1 Agonists Key Players Revenue

Table 2020-2025 South America Glp-1 Agonists Key Players Market Share

Table 2020-2030 South America Glp-1 Agonists Market Size by Type

Table 2020-2030 Brazil Glp-1 Agonists Market Size

Table 2020-2030 Argentina Glp-1 Agonists Market Size

Table 2020-2030 Chile Glp-1 Agonists Market Size

Table 2020-2030 Peru Glp-1 Agonists Market Size

Table 2020-2030 Asia & Pacific Glp-1 Agonists Market Size

Figure 2020-2030 Asia & Pacific Glp-1 Agonists Market Size and CAGR

Table 2020-2030 Asia & Pacific Glp-1 Agonists Market Size by Application

Table 2020-2025 Asia & Pacific Glp-1 Agonists Key Players Revenue

Table 2020-2025 Asia & Pacific Glp-1 Agonists Key Players Market Share

Table 2020-2030 Asia & Pacific Glp-1 Agonists Market Size by Type

Table 2020-2030 China Glp-1 Agonists Market Size

Table 2020-2030 India Glp-1 Agonists Market Size

Table 2020-2030 Japan Glp-1 Agonists Market Size

Table 2020-2030 South Korea Glp-1 Agonists Market Size

Table 2020-2030 Southeast Asia Glp-1 Agonists Market Size

Table 2020-2030 Australia Glp-1 Agonists Market Size

Table 2020-2030 Europe Glp-1 Agonists Market Size

Figure 2020-2030 Europe Glp-1 Agonists Market Size and CAGR

Table 2020-2030 Europe Glp-1 Agonists Market Size by Application

Table 2020-2025 Europe Glp-1 Agonists Key Players Revenue

Table 2020-2025 Europe Glp-1 Agonists Key Players Market Share

Table 2020-2030 Europe Glp-1 Agonists Market Size by Type

Table 2020-2030 Germany Glp-1 Agonists Market Size

Table 2020-2030 France Glp-1 Agonists Market Size

Table 2020-2030 United Kingdom Glp-1 Agonists Market Size

Table 2020-2030 Italy Glp-1 Agonists Market Size

Table 2020-2030 Spain Glp-1 Agonists Market Size

Table 2020-2030 Belgium Glp-1 Agonists Market Size

Table 2020-2030 Netherlands Glp-1 Agonists Market Size

Table 2020-2030 Austria Glp-1 Agonists Market Size

Table 2020-2030 Poland Glp-1 Agonists Market Size

Table 2020-2030 Russia Glp-1 Agonists Market Size

Table 2020-2030 MEA Glp-1 Agonists Market Size

Figure 2020-2030 MEA Glp-1 Agonists Market Size and CAGR

Table 2020-2030 MEA Glp-1 Agonists Market Size by Application

Table 2020-2025 MEA Glp-1 Agonists Key Players Revenue

Table 2020-2025 MEA Glp-1 Agonists Key Players Market Share

Table 2020-2030 MEA Glp-1 Agonists Market Size by Type
Table 2020-2030 Egypt Glp-1 Agonists Market Size
Table 2020-2030 Israel Glp-1 Agonists Market Size
Table 2020-2030 South Africa Glp-1 Agonists Market Size
Table 2020-2030 Gulf Cooperation Council Countries Glp-1 Agonists Market Size
Table 2020-2030 Turkey Glp-1 Agonists Market Size
Table 2020-2025 Global Glp-1 Agonists Market Size by Region
Table 2020-2025 Global Glp-1 Agonists Market Size Share by Region
Table 2020-2025 Global Glp-1 Agonists Market Size by Application
Table 2020-2025 Global Glp-1 Agonists Market Share by Application
Table 2020-2025 Global Glp-1 Agonists Key Vendors Revenue
Figure 2020-2025 Global Glp-1 Agonists Market Size and Growth Rate
Table 2020-2025 Global Glp-1 Agonists Key Vendors Market Share
Table 2020-2025 Global Glp-1 Agonists Market Size by Type
Table 2020-2025 Global Glp-1 Agonists Market Share by Type
Table 2025-2030 Global Glp-1 Agonists Market Size by Region
Table 2025-2030 Global Glp-1 Agonists Market Size Share by Region
Table 2025-2030 Global Glp-1 Agonists Market Size by Application
Table 2025-2030 Global Glp-1 Agonists Market Share by Application
Table 2025-2030 Global Glp-1 Agonists Key Vendors Revenue
Figure 2025-2030 Global Glp-1 Agonists Market Size and Growth Rate
Table 2025-2030 Global Glp-1 Agonists Key Vendors Market Share
Table 2025-2030 Global Glp-1 Agonists Market Size by Type
Table 2025-2030 Glp-1 Agonists Global Market Share by Type

I would like to order

Product name: GLP-1 Agonists Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology

Product link: <https://marketpublishers.com/r/GC9588919AAEEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC9588919AAEEN.html>